ARS Pharmaceuticals (SPRY) Total Current Liabilities (2020 - 2026)

ARS Pharmaceuticals has disclosed Total Current Liabilities across 7 years of filings, most recently posting $49.6 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $49.6 million, up 79.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $49.6 million (up 79.61% YoY), and the FY2025 annual result was $39.1 million, up 67.0% from the prior year.
• Total Current Liabilities came in at $49.6 million for Q1 2026 at ARS Pharmaceuticals, up from $39.1 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $50.9 million in Q3 2025 to a low of $2.4 million in Q4 2023.
• The 5-year median for Total Current Liabilities is $11.2 million (2023), against an average of $19.5 million.
• Across the five-year window, Total Current Liabilities sank 74.0% in 2022 and surged 880.34% in 2024, its largest moves.
• ARS Pharmaceuticals' Total Current Liabilities stood at $5.4 million in 2022, then plunged by 56.08% to $2.4 million in 2023, then soared by 880.34% to $23.4 million in 2024, then jumped by 67.0% to $39.1 million in 2025, then advanced by 26.74% to $49.6 million in 2026.
• The last three Total Current Liabilities figures came in at $49.6 million (Q1 2026), $39.1 million (Q4 2025), and $50.9 million (Q3 2025), per Business Quant data.